SCYNEXIS resolves MARIO study dispute with GSK, receives $22M payment

SCYNEXIS INC

Binding MOU terminates Phase 3 MARIO trial for invasive candidiasis; SCYNEXIS gets $22M from GSK.
Additional $2.3M payment from GSK for wind-down and termination activities.
SCYNEXIS will transfer BREXAFEMME NDA to GSK by end of 2025; GSK plans FDA interactions in 2026 for VVC/rVVC relaunch.
Milestones and royalties for VVC and rVVC indications remain unchanged under the exclusive license agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.